133 related articles for article (PubMed ID: 10737839)
1. Risk of transfusion-transmitted human T-cell lymphotropic virus-type I in Latin America.
Gotuzzo E
Int J Infect Dis; 2000; 4(2):59-61. PubMed ID: 10737839
[TBL] [Abstract][Full Text] [Related]
2. Human T-cell lymphotropic virus-I in Latin America.
Gotuzzo E; Arango C; de Queiroz-Campos A; Istúriz RE
Infect Dis Clin North Am; 2000 Mar; 14(1):211-39, x-xi. PubMed ID: 10738680
[TBL] [Abstract][Full Text] [Related]
3. Screening blood products for HTLV-I: what is the best approach?
Vesilind GW; Koepke JA; DesHarnais GR
Transfus Sci; 1990; 11(1):103-12. PubMed ID: 10149525
[TBL] [Abstract][Full Text] [Related]
4. Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery. A multicenter study of HIV-1 and HTLV-I/II infections.
Nelson KE; Donahue JG; Muñoz A; Cohen ND; Ness PM; Teague A; Stambolis VA; Yawn DH; Callicott B; McAllister H
Ann Intern Med; 1992 Oct; 117(7):554-9. PubMed ID: 1524329
[TBL] [Abstract][Full Text] [Related]
5. Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1.
Donegan E; Lee H; Operskalski EA; Shaw GM; Kleinman SH; Busch MP; Stevens CE; Schiff ER; Nowicki MJ; Hollingsworth CG
Transfusion; 1994 Jun; 34(6):478-83. PubMed ID: 8023388
[TBL] [Abstract][Full Text] [Related]
6. The outcome of donor screening for human T-cell lymphotropic virus infection in The Netherlands.
Prinsze FJ; Zaaijer HL
Vox Sang; 2012 Apr; 102(3):198-203. PubMed ID: 21895678
[TBL] [Abstract][Full Text] [Related]
7. Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model.
Stigum H; Magnus P; Samdal HH; Nord E
Int J Epidemiol; 2000 Dec; 29(6):1076-84. PubMed ID: 11101551
[TBL] [Abstract][Full Text] [Related]
8. Transfusion transmitted human T-lymphotropic virus infections.
Grillner L
Acta Anaesthesiol Scand Suppl; 1988; 89():16-9. PubMed ID: 3067484
[TBL] [Abstract][Full Text] [Related]
9. Saudi National Guard donor screening for human T cell lymphotropic virus I/II: time to use molecular biology techniques.
Balkhy HH; Memish ZA; Abed E; Qasem L; Amer AB; Masoud S; Hajeer AH
Mil Med; 2004 Mar; 169(3):251-3. PubMed ID: 15080248
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of donor screening for HTLV-I and the natural history of transfusion-transmitted infection.
Inaba S; Okochi K; Sato H; Fukada K; Kinukawa N; Nakata H; Kinjyo K; Fujii F; Maeda Y
Transfusion; 1999 Oct; 39(10):1104-10. PubMed ID: 10532605
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the infectious viral load required for transfusion-transmitted human T-lymphotropic virus type 1 infection (TT-HTLV-1) and of the effectiveness of leukocyte reduction in preventing TT-HTLV-1.
Sobata R; Matsumoto C; Uchida S; Suzuki Y; Satake M; Tadokoro K
Vox Sang; 2015 Aug; 109(2):122-8. PubMed ID: 25930000
[TBL] [Abstract][Full Text] [Related]
12. HIV and HTLV-I infections in the Americas: a regional perspective.
Quinn TC; Zacarias FR; St John RK
Medicine (Baltimore); 1989 Jul; 68(4):189-209. PubMed ID: 2544782
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of HTLV-I virus in blood donors and transfusion in Mali: Implications for blood safety.
Diarra AB; Kouriba B; Guindo A; Maiga AI; Diabaté DT; Douyon I; Diawara SI; Touré BA; Fonkoro S; Murphy EL; Diallo DA
Transfus Clin Biol; 2014 Jun; 21(3):139-42. PubMed ID: 24948205
[No Abstract] [Full Text] [Related]
14. Laboratory characterization of human T cell lymphotropic virus types 1 (HTLV-1) and 2 (HTLV-2) infections in blood donors from Sao Paulo, Brazil.
Segurado AA; Malaque CM; Sumita LM; Pannuti CS; Lal RB
Am J Trop Med Hyg; 1997 Aug; 57(2):142-8. PubMed ID: 9288805
[TBL] [Abstract][Full Text] [Related]
15. Risk acceptance of human T-lymphotropic virus infection in solid organ transplantation-A survey of Atlantic Canadian ambulatory patients.
Patriquin G; Hatchette JE; Hatchette TF
Transpl Infect Dis; 2018 Oct; 20(5):e12958. PubMed ID: 29959880
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a post-Columbian introduction of human T-cell lymphotropic virus [type I] [corrected] in Latin America.
Van Dooren S; Gotuzzo E; Salemi M; Watts D; Audenaert E; Duwe S; Ellerbrok H; Grassmann R; Hagelberg E; Desmyter J; Vandamme AM
J Gen Virol; 1998 Nov; 79 ( Pt 11)():2695-708. PubMed ID: 9820145
[TBL] [Abstract][Full Text] [Related]
17. Seroprevalence of human T-lymphotropic virus (HTLV) in blood donors in sub-Saharan Africa: a systematic review and meta-analysis.
Ngoma AM; Omokoko MD; Mutombo PB; Nollet KE; Ohto H
Vox Sang; 2019 Jul; 114(5):413-425. PubMed ID: 30972789
[TBL] [Abstract][Full Text] [Related]
18. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.
Seed CR; Kiely P; Keller AJ
Intern Med J; 2005 Oct; 35(10):592-8. PubMed ID: 16207258
[TBL] [Abstract][Full Text] [Related]
19. Prevention of transmission of human T-cell lymphotropic virus type-I by blood transfusion by screening of donors.
Nishimura Y; Yamaguchi K; Kiyokawa T; Takatsuki K; Imamura Y; Fujiwara H
Transfusion; 1989 May; 29(4):372. PubMed ID: 2718239
[No Abstract] [Full Text] [Related]
20. The epidemiology of human T-cell lymphotropic virus types I and II in Canadian blood donors.
O'Brien SF; Goldman M; Scalia V; Yi QL; Fan W; Xi G; Dines IR; Fearon MA
Transfus Med; 2013 Oct; 23(5):358-66. PubMed ID: 23859527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
